If one can get beyond the fact that (FLML) is a French domiciled company, it has IMO very intriguing issues to consider for a biotech firm. For starters, they are actually one of the few biotechs that are showing earnings and a profit.
|An SI Board Since April 2003|
For me, the reason I've held this stock for several years is my opinion that most of the major drug companies are facing the onslaught of generic drugs eroding their "money-makers" ,and to regain control over these drugs they will need to reformulate them. A new delivery is one way to accomplish this.
What FLML has to offer is a unique and proprietary drug delivery platform. They have several partnerships in this area, but the one that has my attention is the deal(S) they have with Glaxo. Last July(02), they signed a deal with Glaxo for their Augmentin drug. On 3/29/03, Glaxo signed another deal with FLML...indicating at least to me, they like what they have seen with the '02 Augmentin deal.
FLML has several other undisclosed product develop deals with major companies.
Also, on 3/25.03, FLML announce positive results for their Basulin diabetic product. They are seeking a partnership for this product...and any announcement with a major company will be a major positive.
FLML has been very strong in 2003..Currently it is up about 70% YTD, and if you look at the current TA for the stock you will find...
If one follows TA on stocks, then the current chart on FLML indicates that better things are ahead....
"FLML shows a substantial positive divergence from its 200-day moving average line of more than 75%. Generally, the greater the difference between a stock's price and this important long-term technical indicator, the steeper will be that stock's long-term uptrend. A divergence this large from the 200-day line ranks in the top five percent of the market and is a bullish indication of long-term strength for FLML."
I have owned this stock for three years...and recently added more. Would welcome any discussion.